Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sheri Dodds

Clinical Nurse Specialist, Family Health Lancaster, OH Nurse Practitioner

NPI 1194782987 CMS profile 10638791

220 E Walnut St, Lancaster, OH 43130

Open in the dashboard

General payments

$2,320

132 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sheri Dodds of Lancaster, OH is reported in the CMS Open Payments database as having received $2,320 across 132 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Clinical Nurse Specialist, Family Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $400 21
2024 General $339 15
2023 General $498 21
2022 General $579 41
2021 General $505 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sheri Dodds
  • Clinical Nurse Specialist, Family Health median
  • Middle half of Clinical Nurse Specialist, Family Health
  • National median

In program year 2025, general payments to Sheri Dodds were reported at $400. Among 164 Clinical Nurse Specialist, Family Health profiles paid that year, the median was $216 and the middle half received between $57 and $492.

Show as a table
Year Sheri Dodds Clinical Nurse Specialist, Family Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $505 $151 $46–$400 $132
2022 $579 $153 $37–$527 $149
2023 $498 $139 $50–$451 $160
2024 $339 $150 $46–$571 $164
2025 $400 $216 $57–$492 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Astellas Pharma US Inc $606 22 payments
  2. Amgen Inc. $364 28 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $230 16 payments
  4. Novo Nordisk Inc $164 11 payments
  5. AbbVie, Inc. $129 7 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $100 6 payments
  7. Grifols USA, LLC $99 6 payments
  8. Exact Sciences Corporation $65 4 payments
  9. Pfizer Inc. $62 3 payments
  10. Xeris Pharmaceuticals, Inc. $58 3 payments
  11. Other $443 26 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,135 130 payments
  2. Education $185 2 payments
Products named General payments · program years 2021–2025
  1. Veozah $387 18 payments
  2. Repatha $283 23 payments
  3. Otezla $246 20 payments
  4. Ozempic $146 10 payments
  5. STIOLTO RESPIMAT $126 8 payments
  6. RYBELSUS $120 8 payments
  7. Kerendia $100 6 payments
  8. Prolastin-C Liquid $99 6 payments
  9. AIMOVIG $82 6 payments
  10. EVENITY $81 5 payments
  11. Other $1,174 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

68

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$5,876

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

80.9%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Premarin Estrogens, Conjugated Brand 11 $4,783
Alyacen Norethindrone-Ethin. Estradiol Brand 18 $460
Medroxyprogesterone Acetate Generic 13 $411
Junel Fe Norethindrone-E.Estradiol-Iron Brand 11 $170
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 15 $52

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $246
$246 — —
VRAYLAR
  • AbbVie, Inc. $25
$25 — —
NURTEC ODT
  • PFIZER INC. $19
$19 — —
ZAVZPRET
  • PFIZER INC. $19
$19 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

132 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Family Health in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record